CURRENT TRENDS IN THE MANAGEMENT OF CYTOMEGALOVIRUS IN CELL THERAPIES RECIPIENTS IN SPAIN: RESULTS OF THE 2025 GETH-TC SURVEY (EBMT 2026) - Mar 14, 2026 - Abstract #B117; Pres time: Mar 24, 2026; 06:00 PM - 07:00 PM; Location: VELAZQUEZ; " A structured online survey addressing 5 domains—use of letermovir (LMV), use of maribavir (MBV), advanced diagnostic tools, management of CAR-T/BITE recipients, and implementation of ECIL-10 recommendations—was distributed in May 2025 to adult and paediatric hematologists within the GETH-TC...Among recipients receiving post-transplant cyclophosphamide, 50% prescribed LMV only in the presence of additional risk factors... The 2025 GETH-TC survey demonstrates widespread adoption of modern CMV prevention and treatment strategies in Spain, including universal LMV use for primary prophylaxis and broad extension beyond day +100. MBV is increasingly integrated into the management of refractory or resistant CMV. Diagnostic practices are also evolving, with expanded use of resistance testing and immune reconstitution assessment."
Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Immunology
|
|
I. García-Cadenas1; R. Martino1; M. C. Viguria2; A. J. González-Huerta3; I. Heras4; M. Huguet5; A. Sánchez-Salinas6; P. Chorao7; A. Bienert8; T. Torrado9; A. Cantalapiedra10; S. Villar11; Chinea A12; L. Vázquez13; M. Suárez- Lledó14; M. Sánchez-Escamilla15; L. González-Pinedo16; F. Peña-Muñoz17; C. Rivera18; I. Torija19; M. González-Vicent20; F. Martín-Domínguez21; I. Gómez-Centurión22; N. Alonso23; E. Iranzo1; S. Filaferro24; P. Balsalobre24; D. Navarro25; R. De la Cámara26; Jl Piñana27
|